We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Largest Study to Date Examines CT Scanning for Prevention of Heart Disease

By MedImaging staff writers
Posted on 22 Apr 2008
Calcium deposits in coronary arteries are a strong predictor for possible future heart attacks and cardiac diseases, and detecting such deposits can be valuable for promoting overall cardiac health, according to a new study utilizing computed tomography (CT) scanning.

Supported by the U.S. More...
National Institutes of Health (NIH; Bethesda, MD, USA), the study, led by researchers from the University of California (UC), Irvine (USA) and appearing in the March 28, 2008, issue of the New England Journal of Medicine (NEJM) is the largest involving CT scanning to date--testing some 6,700 people in the United States. It is also the first study to include racially and ethnically diverse participants. Previous coronary calcium studies featured only small enrollments of white patients.

"The results prove that coronary calcium detection is a strong predictor of heart attack and disease for African Americans, Hispanics, and Chinese Americans as well,” said Dr. Robert Detrano, professor of radiological sciences at UC Irvine and study leader. "It wasn't known before whether this would be effective for other racial and ethnic groups, and this study answers that important question.”

Coronary calcium is detected by CT scanning; a noninvasive procedure that, for calcium identification, does not require injected contrast. The procedure focuses on the coronary arteries, which supply blood to the heart and are particularly vulnerable to calcium buildup. The researchers discovered that participants with moderate deposit amounts had more than a seven times greater risk of cardiac heart disease compared to people with no coronary calcium buildup. Participants with large deposit amounts faced a 10 times greater risk.

Coronary calcium is a marker for a diseased artery. It accumulates similar to atherosclerotic plaque and is caused by the same primary factor--high blood lipid levels. According to Dr. Detrano, calcium screening can be recommended for people who are at moderate risk. "This is a very practical and effective method for cardiac disease and heart attack prevention,” stated Dr. Detrano, who had proposed the study of calcium screening as early as 1989. "One of the factors we need to address is cost; it behooves the imaging industry to bring the cost down and make this procedure available to everyone.”

According to Dr. Detrano, the current cost for a CT scan is between US$300 and $600 per exam. However, he believes that costs can be lower. In his work diagnosing and treating cardiac diseases in rural China, Dr. Detrano performs CT research scans for as little as $30.

Detrano added that these results also contribute to his clinical efforts in China. Before the study, he said, it had not been established that coronary calcium detection could predict future cardiac diseases and heart attacks in Chinese people. Through UC Irvine and the China-California Heart Watch, a not-for-profit organization of which he is president, Dr. Detrano leads clinical efforts in poor rural regions of southern China where cardiac care is deficient or nonexistent.

For the study, Dr. Detrano and his colleagues performed coronary calcium scanning on 6,722 men and women at U.S. sites in Los Angeles, CA; New York City, NY; Baltimore, MD; Chicago, IL; St. Paul, MN; and Forsythe County, NC. Thirty-nine percent of the participants were Caucasian, 28% African-American, 22% Hispanics, and 12% Chinese. Participants entered the study without cardiovascular disease and they were followed for an average of 3.8 years.


Related Links:
University of California, Irvine
China-California Heart Watch

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.